Harada Koji, Tamatani Tetsuya, Bando Takashi, Yoshida Hideo
Department of Therapeutic Regulation for Oral Tumors, Graduate School of Health and Bioscience, Tokushima University.
Gan To Kagaku Ryoho. 2007 Sep;34(9):1455-8.
A 76-year-old patient with oral squamous cell carcinoma was treated by chemotherapy with S-1. S-1 (100 mg/body/day) was orally administered for 4 weeks followed by a 2-week rest period as one course. The primary lesion markedly decreased at 7 days after the beginning of S-1 treatment, and disappeared after one course of S-1. After two courses, the primary lesion was assessed to show a complete response (CR),and no tumor cells were identified as a result of biopsy. In addition, the value of tumor marker SCC decreased from 2.13 ng/mL before treatment to 0.68 ng/mL after two courses of S-1. Although the patient is still taking UFT, she is well with no signs of recurrence 50 months from the initial treatment.
一名76岁的口腔鳞状细胞癌患者接受了S-1化疗。S-1（100毫克/体/天）口服给药4周，随后休息2周作为一个疗程。S-1治疗开始7天后，原发灶明显缩小，一个疗程后消失。两个疗程后，评估原发灶显示完全缓解（CR），活检未发现肿瘤细胞。此外，肿瘤标志物SCC的值从治疗前的2.13纳克/毫升降至S-1两个疗程后的0.68纳克/毫升。尽管该患者仍在服用优福定，但自初始治疗50个月以来，她情况良好，没有复发迹象。
